Literature DB >> 23075870

Nonalcoholic fatty liver disease: what the pathologist can tell the clinician.

Elizabeth M Brunt1.   

Abstract

Liver biopsy evaluation continues to serve a significant, often primary, role in clinical care, as well as in fundamental aspects of investigation in nonalcoholic fatty liver disease (NAFLD). This is a review of the major features of liver pathology in NAFLD and specifically what role liver biopsy continues to play in both clinical management and scientific investigation. Diagnostic criteria for NAFLD and nonalcoholic steatohepatitis in adults and children are discussed, as are other histologic features that may be encountered. Histologic features for diagnostic classification(s) of NAFLD and semiquantitative methods of assessment are reviewed. The unique patterns of injury and fibrosis that characterize this disease are emphasized, and reasons why histologic scoring and diagnosis are considered as interrelated but separate exercises given. In addition, pros and cons and recognized limitations of liver biopsy in NAFLD are discussed.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23075870     DOI: 10.1159/000341127

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  18 in total

Review 1.  Epidemiology of fatty liver: an update.

Authors:  Giorgio Bedogni; Valerio Nobili; Claudio Tiribelli
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 2.  Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Authors:  Yoshihisa Takahashi; Toshio Fukusato
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

3.  Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis.

Authors:  Yan Wang; Robert Vincent; Jinlian Yang; Amon Asgharpour; Xieer Liang; Michael O Idowu; Melissa J Contos; Kalyani Daitya; Mohammed S Siddiqui; Faridoddin Mirshahi; Arun J Sanyal
Journal:  Hepatology       Date:  2017-04-28       Impact factor: 17.425

4.  Nonalcoholic fatty liver may increase the risk of operation in patients with fatty liver and the frequency of cancer in their first-degree relatives.

Authors:  Metin Basaranoglu; Billur Canbakan; Kemal Yildiz; Bahadir Ceylan; Birol Baysal; Omer Uysal; Hakan Senturk
Journal:  Wien Klin Wochenschr       Date:  2015-04-14       Impact factor: 1.704

Review 5.  Circadian rhythms: a possible new player in non-alcoholic fatty liver disease pathophysiology.

Authors:  Davide Gnocchi; Carlo Custodero; Carlo Sabbà; Antonio Mazzocca
Journal:  J Mol Med (Berl)       Date:  2019-04-05       Impact factor: 4.599

Review 6.  Role of liver biopsy in nonalcoholic fatty liver disease.

Authors:  I L Ke Nalbantoglu; Elizabeth M Brunt
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

7.  Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.

Authors:  Miriam B Vos; Lara Dimick-Santos; Ruby Mehta; Stephanie O Omokaro; Johannes Taminiau; Elmer Schabel; David E Kleiner; Peter Szitanyi; Piotr Socha; Jeffrey B Schwimmer; Stephanie Noviello; Debra G Silberg; Richard Torstenson; Veronica Miller; Joel E Lavine
Journal:  Gastroenterology       Date:  2019-09-12       Impact factor: 22.682

8.  A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass.

Authors:  Glenn S Gerhard; Amanda M Styer; G Craig Wood; Stephen L Roesch; Anthony T Petrick; Jon Gabrielsen; William E Strodel; Christopher D Still; George Argyropoulos
Journal:  Diabetes Care       Date:  2013-07       Impact factor: 19.112

Review 9.  Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications.

Authors:  Federica Del Chierico; Daniela Gnani; Pamela Vernocchi; Andrea Petrucca; Anna Alisi; Bruno Dallapiccola; Valerio Nobili; Putignani Lorenza
Journal:  Int J Mol Sci       Date:  2014-01-07       Impact factor: 5.923

Review 10.  MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma.

Authors:  Manuele Gori; Mario Arciello; Clara Balsano
Journal:  Biomed Res Int       Date:  2014-03-13       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.